- Home
- TCBS vs STTK Comparison
TCBS vs STTK Comparison
Compare TCBS & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TCBS
- STTK
- Stock Information
- Founded
- TCBS 1934
- STTK 2016
- Country
- TCBS United States
- STTK United States
- Employees
- TCBS N/A
- STTK N/A
- Industry
- TCBS Banks
- STTK Biotechnology: Pharmaceutical Preparations
- Sector
- TCBS Finance
- STTK Health Care
- Exchange
- TCBS Nasdaq
- STTK Nasdaq
- Market Cap
- TCBS 48.7M
- STTK 49.3M
- IPO Year
- TCBS N/A
- STTK 2020
- Fundamental
- Price
- TCBS $16.18
- STTK $1.88
- Analyst Decision
- TCBS
- STTK Hold
- Analyst Count
- TCBS 0
- STTK 6
- Target Price
- TCBS N/A
- STTK $2.67
- AVG Volume (30 Days)
- TCBS 2.4K
- STTK 1.6M
- Earning Date
- TCBS 08-01-2025
- STTK 08-14-2025
- Dividend Yield
- TCBS 0.99%
- STTK N/A
- EPS Growth
- TCBS N/A
- STTK N/A
- EPS
- TCBS 0.80
- STTK N/A
- Revenue
- TCBS $14,831,000.00
- STTK $2,997,000.00
- Revenue This Year
- TCBS N/A
- STTK N/A
- Revenue Next Year
- TCBS N/A
- STTK N/A
- P/E Ratio
- TCBS $20.17
- STTK N/A
- Revenue Growth
- TCBS 51.57
- STTK N/A
- 52 Week Low
- TCBS $14.39
- STTK $0.69
- 52 Week High
- TCBS $19.40
- STTK $3.95
- Technical
- Relative Strength Index (RSI)
- TCBS 54.13
- STTK 85.01
- Support Level
- TCBS $15.75
- STTK $0.97
- Resistance Level
- TCBS $16.62
- STTK $1.05
- Average True Range (ATR)
- TCBS 0.12
- STTK 0.15
- MACD
- TCBS 0.01
- STTK 0.09
- Stochastic Oscillator
- TCBS 48.85
- STTK 94.35
About TCBS Texas Community Bancshares Inc.
Texas Community Bancshares Inc is a holding company. The company's business consists of taking deposits from the general public and investing those deposits, together with funds generated from operations and borrowings from the Federal Home Loan Bank of Dallas, in residential real estate loans and commercial real estate loans and, to a lesser extent, commercial loans, construction and land loans, and consumer and other loans. Its portfolio segments are real estate, agriculture, commercial, consumer and other.
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.